aKRAS: Lead candidate in colorectal cancer

Oblique has developed aKRAS with the Abiprot™ platform: antagonistic antibodies with single amino acid selectivity against mutated KRAS.

About KRAS-mutated colorectal cancer

Sometimes referred to as bowel and colon cancer, colorectal cancer is a malignancy of the intestine. According to recent reports from WHO, around 1.8 million people were estimated to develop the disease in 2018, making it the third-most prevalent type of cancer in the world. Although significant progress has been made in colorectal cancer treatment in the past decade, with the approval of several new agents, such as VEGF and EGFR-targeted therapies, the prognosis for patients with colorectal cancer remains poor.

Nearly 900, 000 people were estimated to succumb to the disease in 2018 alone. Resistance to therapy remains a major obstacle to effective treatment and many patients do not receive any clinical benefit from standard-of-care treatment. A mediator of resistance to anti-EGFR therapy is a mutation in the KRAS gene, a genetic driver for malignant transformation, found in approximately 30–50% of cases.

Market potential

In 2018, it was estimated that 540, 000–900, 000 individuals would develop KRAS-mutated colorectal cancers and were therefore likely to see little to no benefit from the standard-of-care EGFR-targeted treatments. The KRAS-mutated market in the seven major markets (Germany, France, Italy, Japan, Spain, UK and the US) is estimated at between roughly USD 1.65 to 2.75 billion annually and is expected to grow.

1. Markman, M. W. M. L. “Colorectal cancer and KRAS/BRAF.” Medscape (2014). Updated 2018. Accessed 24 September 2018.

2. Wilson PM, Labonte MJ, Lenz HJ. Molecular markers in the treatment of metastatic colorectal cancer. Cancer J. 2010 May-Jun. 16(3):262-72.

3. Porru, Manuela, et al. “Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.” Journal of Experimental & Clinical Cancer Research 37.1 (2018): 57.

4. Datamonitor Healthcare Colorectal Cancer Patient based Forecast Report 2016-2015